Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Asian Equities Traded in the US as American Depositary Receipts Advance Sharply in Monday Trading

Asian Equities Traded in the US as American Depositary Receipts Advance Sharply in Monday Trading

MT newswireMT newswire2026/11/09 14:45
10:45 AM EST, 11/09/2026 (MT Newswires) -- Asian equities traded in the US as American depositary receipts were trending sharply higher Monday morning, surging 1.58% to 2,893.83 on the S&P Asia 50 ADR Index. From North Asia, the gainers were led by biopharmaceutical company Zai Lab (ZLAB) and semiconductor company ASE Technology (ASX), which climbed 7.1% and 8.4% respectively. They were followed by lender Sumitomo Mitsui Financial Group (SMFG) and used car marketplace Uxin (UXIN), which advanced 3.2% and 8.4%, respectively. The decliners from North Asia were led by solar panel maker Jinko (JKS) and polysilicon manufacturer Daqo New Energy (DQ), which dropped 5.6% and 6.6% respectively. They were followed by automotive marketplace Token Cat (TC) and online entertainment service iQIYI (IQ), which fell 0.7% and 4.5% respectively. From South Asia, the gainers were led by tech conglomerate Sea (SE) and IT firm Sify Technologies (SIFY), which rose 3.5% and 3.4% respectively. They were followed by lender HDFC Bank (HDB) and telecommunications operator Telekomunikasi Indonesia (TLK), which were up 2.2% and 1.8% respectively. The decliners from South Asia were led by telecommunications operator PLDT (PHI) and computer hardware maker Canaan (CAN), which lost 2% and 0.6% respectively. They were followed by pharmaceutical company Dr. Reddy's Laboratories (RDY), which was off 0.6%.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

From $617 to $350: CVS Sets "Break-Even Price" for Weight-Loss Drugs, Says Pharmaceutical Companies Can Still Profit

An analysis of insurance claims data found that if GLP-1 drugs used for weight loss and diabetes are priced below $350 per month, payers—such as employers and plan sponsors—would achieve net savings due to a decrease in related healthcare service utilization.

智通财经•2026/11/15 04:01
From $617 to $350: CVS Sets "Break-Even Price" for Weight-Loss Drugs, Says Pharmaceutical Companies Can Still Profit

UNI falls below $5

金色财经•2026/11/15 03:37
UNI falls below $5